By Marcia Dunn

Stargazers are in for a double treat on Aug. 30: a rare blue supermoon with Saturn peeking from behind.

The cosmic curtain rises Wednesday night with the second full moon of the month, the reason it’s considered blue. It’s dubbed a supermoon because it’s closer to Earth than usual, appearing especially big and bright.

This will be the closest full moon of the year, just 222,043 miles (357,344 kilometers) or so away. That’s more than 100 miles (160 kilometers) closer than the Aug. 1 supermoon.

As a bonus, Saturn will be visible as a bright point 5 degrees to the upper right of the moon at sunset in the east-southeastern sky, according to NASA. The ringed planet will appear to circle clockwise around the moon as the night wears on.

If you missed the month’s first spectacle, better catch this one. There won’t be another blue supermoon until 2037, according to Italian astronomer Gianluca Masi, founder of the Virtual Telescope Project.

Clouds spoiled Masi's attempt to livestream the supermoon rising earlier this month. He’s hoping for clearer skies this time so he can capture the blue supermoon shining above St. Peter’s Basilica at the Vatican.

Weather permitting, observers don’t need binoculars or telescopes — “just their own eyes." said Masi.

“I’m always excited to admire the beauty of the night sky,” he said, especially when it features a blue supermoon.

The first supermoon of 2023 was in July. The fourth and last will be in September.

Share:
More In Science
As U.S. Opioid Crisis Worsens, Price of Life-Saving Drug Naloxone Skyrockets
Jill Wagner and Baker Machado break down the state of the Opioid Crisis in the U.S. The CDC reported a 30% increase in overdose deaths from 2020 to 2021, but in recent months pharmaceutical companies have drastically raised the price of Naloxone or 'Narcan,' affecting the response of community harm prevention groups.
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Legal Questions Swirl as States Push Back Against Biden COVID Vaccine Mandate
The Biden Administration's mandate for COVID vaccinations by large employers has been put on hold by federal courts as GOP-led states and some businesses push back on the order's legality. Jonathan Adler, a law professor at Case Western Reserve University, joined Cheddar to discuss the legal challenges to implementing such mandates through OSHA (Occupational Safety and Health Administration). "Certainly expanding vaccinations is a good thing, and as vaccination rates go up that's better for all of us," Adler said. "But there are some legal questions about whether or not it's appropriate to use a law about occupational safety and health as the means to do that."
What COVID-19 Vaccines for Kids Might Mean for Fight Against Pandemic
Dr. Robert Frenck, an infectious disease specialist at Cincinnati Children's Hospital, joined Cheddar to talk about the significance of children ages 5-11 being authorized to receive COVID-19 vaccinations. He also discussed schools being cleared to administer vaccines and noted the importance of meeting people where they are rather than forcing them to find the shots. Frenck also said he expects that children under 5 years old will begin getting vaccinations sometime in spring.
Everything You Need to Know About Child Covid-19 Vaccines
A CDC advisory committee as unanimously voted to recommend the Pfizer Covid-19 vaccine in children ages 5 to 11. Dr. Amesh Adalja, Infectious Disease Specialist and Senior Scholar at Johns Hopkins Center for Health Security, joined Cheddar News to discuss.
Load More